WO2001028513A2 - Pastilles de bain - Google Patents

Pastilles de bain Download PDF

Info

Publication number
WO2001028513A2
WO2001028513A2 PCT/EP2000/009834 EP0009834W WO0128513A2 WO 2001028513 A2 WO2001028513 A2 WO 2001028513A2 EP 0009834 W EP0009834 W EP 0009834W WO 0128513 A2 WO0128513 A2 WO 0128513A2
Authority
WO
WIPO (PCT)
Prior art keywords
phase
weight
tablet system
acid
care
Prior art date
Application number
PCT/EP2000/009834
Other languages
German (de)
English (en)
Other versions
WO2001028513A3 (fr
Inventor
Detlef Hollenberg
Ullrich Bernecker
Britta Bossmann
Original Assignee
Henkel Kommanditgesellschaft Auf Aktien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Kommanditgesellschaft Auf Aktien filed Critical Henkel Kommanditgesellschaft Auf Aktien
Priority to AU28340/01A priority Critical patent/AU2834001A/en
Publication of WO2001028513A2 publication Critical patent/WO2001028513A2/fr
Publication of WO2001028513A3 publication Critical patent/WO2001028513A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/22—Gas releasing
    • A61K2800/222—Effervescent

Definitions

  • the invention relates to a multi-phase cosmetic bath tablet system, the phases of which dissolve in water at different times or at different times and first develop a cleaning and then a nourishing effect.
  • Effervescent tablets release carbon dioxide on contact with water, which has a pleasant metabolic stimulating and invigorating effect on the skin and also significantly improves blood circulation.
  • auxiliary substances such as fillers, binders, disintegrants and lubricants.
  • No. 5,002,758 describes a bath additive which, in addition to fumaric acid and a carbonate, contains carboxymethyl cellulose and a nonionic surfactant.
  • FR 2 152 810 relates to a bath additive in tablet form which contains an "effervescent powder" and a urea derivative as a binder.
  • US Pat. No. 4,666,707 relates to weakly acidic bath salt compositions based on a carbonate, an acid and a humectant.
  • US Pat. No. 4,650,667 describes bath additives which besides "Carbonates and acids contain a stabilizer.
  • EP 0 930 064 relates to single-phase, bubbly carbonate / bicarbonate-based bath tablets which, in addition to lipid components, contain vesicle-forming lipids and W / O and / or O / W surfactants.
  • EP 0 498 272 describes bath additives in tablet form, which release carbon dioxide and contain a colloidal material. With these bath tablets consisting of one layer, it is inevitably not possible to separate skin cleansing and nourishing after-treatment of the skin in time l The resulting sticking of the mass, which makes shaping impossible, gave rise to the development of specially constructed multi-layer bathing tablets (JP 03074321 A).
  • the task was to combine the convenient handling that bath additives in tablet form offer with high cleaning power and a high level of care in the form of a bath tablet for body cleaning. Intensive skin cleaning should not be prevented by caring ingredients, so skin cleaning and care should take place at different times in the bath.
  • this object can be achieved in the form of a multi-phase bath tablet system, the phases of which dissolve in water at different speeds or at different times (with a time delay). While the surfactant-containing cleansing phase dissolves quickly and enables intensive cleaning at the beginning of the bath, the phase containing the care components dissolves more slowly or with a time delay and allows the skin to be treated afterwards.
  • the invention therefore relates to a multi-phase bath tablet system with different dissolving times of the phases, characterized in that it has at least one rapidly dissolving cleaning phase containing an effervescent system and a surfactant or surfactant mixture and at least one care phase which dissolves slowly or with a time delay and contains at least one care component , contains.
  • a bathing tablet system is preferably suitable for the cleaning and care treatment of the skin and the appendages of the skin, e.g. B. the hair or nails.
  • Suitable moldings and the technology for producing such moldings are known to the person skilled in the art and are u. a. described in DE 197 39 384 and in DE 197 54 289.
  • the bathing tablet system is made up of at least two different phases. It can be formulated as a two- or preferably a three-layer tablet, although a structure of more than three layers can be advantageous for certain applications.
  • a stack-like layer structure enables the spatial separation of components that may have a mutually negative effect. The decay and that Dissolution of the layers can be controlled in a targeted manner via the composition of the layers and the incorporation of disintegration aids.
  • a three-layer tablet contains the care component (s) in the inner layer, which dissolves more slowly or with a delay, while the two outer layers, which dissolve quickly, contain surfactants.
  • a further preferred embodiment is characterized in that the bathing tablet system is constructed from a core and a jacket, the core containing the care component (s) and the jacket containing the shower system and the surfactant or surfactant mixture.
  • the cleaning effect begins and is not negatively influenced by the care components of the core.
  • the dissolving of the core occurs with a time delay and enables a neat after-treatment of the skin during the bath.
  • the dissolution time of the cleaning phase is suitably in the range of 1-5 minutes, that of the care phase is 7-15 minutes.
  • the multi-phase bath tablet system can preferably also contain two individual tablets, ie a cleaning and a maintenance tablet, which are located in a sales unit - packed together or separately - and are intended for simultaneous use.
  • the individual tablets like the multiphase tablets, dissolve at different speeds, so that here too intensive skin cleaning takes place before the aftercare treatment.
  • shower systems are understood to mean a substance or a mixture of substances which releases a gas on contact with water (for example carbon dioxide, oxygen, nitrogen, etc.).
  • the shower system is included in the rapidly dissolving, cleaning phase and causes this phase to disintegrate quickly and the active components to be released quickly.
  • the cleaning phase preferably contains 40.0-90.0% by weight of the shower system.
  • the disintegration time of the cleaning phase is approx. 1 - 5 minutes.
  • the gas released from the effervescent system will usually be carbon dioxide, but the release of oxygen from suitable, physiologically acceptable peroxo compounds or oxygen-laden zeolites can also be advantageous.
  • a carbon dioxide-producing shower system contains at least two components, e.g. B.
  • a carbonic acid salt and an acidifying agent that react with each other in water Preferred components are alkali metal carbonates and / or hydrogen carbonates and an acidifying agent which is capable of releasing carbon dioxide from the carbonates / hydrogen carbonates in aqueous solution. Suitable combinations can easily be determined by the person skilled in the art on the basis of the pK values.
  • a preferred embodiment of the tablet system is characterized in that the cleaning phase contains an effervescent system consisting of an anhydrous mixture of at least one water-soluble salt of carbonic acid and at least one acidifying agent.
  • the cleaning phase contains an effervescent system consisting of an anhydrous mixture of at least one water-soluble salt of carbonic acid and at least one acidifying agent.
  • embodiments with a mixture of several carbonates / bicarbonates and acidifying agents may also be advantageous.
  • a preferred embodiment of the tablet system is characterized in that it contains anhydrous sodium hydrogen carbonate and / or anhydrous sodium carbonate as the carbonic acid salt.
  • Acidifying agents which release carbon dioxide from the alkali salts in aqueous solution are, for example, boric acid and alkali metal hydrogen sulfates, alkali metal dihydrogen phosphates and other inorganic salts.
  • organic acidifying agents in particular water-soluble ones, are preferably used.
  • mono-, di- and tricarboxylic acids and in particular the solid mono-, oligo- and polycarboxylic acids can be used. From the group of dicarboxylic acids, oxalic acid, malonic acid, succinic acid, adipic acid, fumaric acid, maleic acid, glutaric acid, glutamic acid and pimelic acid are preferred.
  • the cleaning phase of the tablet system contains at least one hydroxycarboxylic acid as an acidifying agent.
  • fruit acids such as, for example, citric acid, lactic acid, malic acid, tartaric acid, gluconic acid, pyrrolidone carboxylic acid and glycolic acid
  • Citric acid is particularly preferred among the hydroxycarboxylic acids. It is characterized by its excellent water solubility and its physiological harmlessness.
  • the use of mono- and diesters of citric acid can also be advantageous.
  • Sokalan® DCS manufactured by BASF
  • succinic acid max. 31% by weight
  • glutaric acid max. 50% by weight
  • adipic acid max 33% by weight
  • the amounts of carbonate / bicarbonate and acidifying agent used influence the pH of the bath water, the amount of carbon dioxide released and the rate of decay of the cleaning phase.
  • the amounts to be used are adjusted accordingly by the person skilled in the art depending on the requirement profile.
  • the equivalent ratio between the salt of carbonic acid and the acidifying agent is between 0.1 and 20.0, preferably between 1.0 and 5.0 and in particular between 1.0 and 2.5. If necessary, salts are added to the shower system, which are used for buffering.
  • a suitable buffer system contains, for example, equal proportions of citric acid and trisodium citrate.
  • Disintegration aids so-called tablet disintegrants, are used to shorten the disintegration times of highly compressed moldings.
  • tablet disintegrants or disintegration accelerators are understood to mean auxiliaries which are required for faster disintegration of tablets in aqueous media.
  • Tablet disintegrants can be divided into hydrophilizing agents, gas-releasing systems and swelling disintegrants.
  • the cleaning phase of the tablet system contains at least one further disintegration aid, which in an amount of 0.1-20% by weight, preferably 0.1-10% by weight and in particular 0.1-5% by weight is included. By adding it, the dissolution time of the cleaning phase can be reduced even further and optimized without any problems.
  • Additional disintegrants / disintegration aids are, for. B. starches, cellulose and cellulose derivatives, alginates, dextrans, cross-linked polyvinylpyrrolidones and polyvinyl alcohols, gelatin, formaldehyde casein, but also typically inorganic substances such as a wide variety of clay minerals (e.g. bentonite) as well as Aerosil® (silica) and certain ion exchange resins (Amberlit®). Further suitable disintegration aids are described in detail in DE 19710254, DE 19722832 and DE 19723028.
  • the disintegration aid is preferably selected from the natural and synthetic polysaccharides and their derivatives.
  • These groups include, for example, the pure polysaccharides starch and cellulose, but also the products from esterifications or etherifications in which hydroxy hydrogen atoms have been substituted. Celluloses or starches in which the hydroxyl groups have been replaced by functional groups which are not bonded via an oxygen atom can also be used as polysaccharide derivatives.
  • the group of cellulose derivatives includes, for example, alkali celluloses, carboxymethyl cellulose (CMC), cellulose esters and ethers and aminocelluloses.
  • the group of starch derivatives includes, for example, carboxymethyl starch (CMS).
  • a particularly preferred embodiment of the tablet system contains at least one cellulose in the cleaning phase as disintegration aid.
  • celluloses available from Save Meier under the name Arbocel® TF 00G and Arbocel ® FT 600 / 30H, preferably suitable. In the sense of the invention it can also be advantageous to use cellulose in granular or cogranular form.
  • the surfactants which can be used according to the invention include anion, nio and amphoteric side.
  • the addition of small amounts of cationic and zwitterionic surfactants may be advantageous, as long as they are compatible with the other components of the bathing tablet.
  • a preferred embodiment of the tablet system is characterized in that the cleaning phase contains 1-40% by weight (based on the weight of this phase) of a surfactant or surfactant mixture.
  • the surfactant or surfactant mixture is preferably present in an amount of 10-30% by weight, in particular 10-20% by weight.
  • Preferred surfactants for the purposes of the invention are water-soluble, i.e. H. they have a solubility of at least 1 g in 11 water at 25 ° C.
  • the tablet preferably contains foam-rich water-soluble surfactants.
  • foam-rich water-soluble surfactants include, for example, anionic surfactants or a combination of anionic surfactants with alkyl polyglycosides.
  • Preferred anionic surfactants are solid or powdered alkyl sulfates, alkyl ether carboxylates, isethionates such as. B. acyl isethionates, alkyl sulfosuccinates and the monoesters of sulfosuccinates. But also alkyl sulfonates, alkyl ether sulfates and sulfonates, alkyl succinates, diesters of sulfosuccinates, N-acyl sarcosinates and N-acyl taurines with linear alkyl or acyl groups (12 - 18 C atoms) can be used in amounts that enable tableting without sticking.
  • the anionic surfactants are usually used in the form of their alkali, magnesium, ammonium or alkanol-ammonium salts.
  • Preferred alk (en) yl sulfates are the alkali and, in particular, the sodium salts of the sulfuric acid half-esters of C 12 -C 18 fatty alcohols from natural fats, for example coconut oil alcohol, tallow fatty alcohol, lauryl, myristyl, cetyl and stearyl alcohol. Also suitable are the alkali and sodium salts of the sulfuric acid half esters of the C 10 -C 20 oxo alcohols and the half esters of secondary alcohols of these chain lengths.
  • alk (en) yl sulfates of the chain length mentioned which contain a synthetic, petrochemical-based, straight-chain alkyl radical which contains a have the same degradation behavior as the adequate compounds based on oleochemical raw materials.
  • the C 12 -C 16 alkyl sulfates and in particular the C 12 -C 14 alkyl sulfates are preferred.
  • Suitable 2-alkyl sulfates which are produced, for example, according to US Pat. Nos. 3,234,258 or 5,075,041, are also suitable anionic surfactants.
  • Alkyl ether sulfates show excellent foam properties.
  • Preferred from this group are sulfuric acid monoesters of straight-chain or branched C 7-21 alcohols ethoxylated with 1 to 6 mol of ethylene oxide, such as 2-methyl-branched with an average of 3.5 moles of ethylene oxide (EO) or C 12-18 fatty alcohols with 1 to 4 EO. Because of their good foaming behavior, they can also be used in relatively small quantities.
  • sulfated fatty acid glycerol esters are sulfated fatty acid glycerol esters.
  • Fatty acid glycerol esters are to be understood as meaning the mono-, di- and triesters and their mixtures as obtained in the production by esterification of one mole of glycerol with 1 to 3 moles of fatty acid or in the transesterification of triglycerides with 0.3 to 2 moles of glycerol
  • Preferred sulfated fatty acid glycerol esters are the esters of saturated fatty acids having 6 to 22 carbon atoms, for example caproic acid, caprylic acid, capric acid, myristic acid, lauric acid, palmitic acid, stearic acid or behenic acid.
  • alkylphenol ether sulfates C 5 -C 17 -acyl-N- (C 1 -C 4 ) -alkylglucamine sulfates and -N- (C 1 -C 2 -hydroxyalkyl) glucamine sulfates as well as sulfates of alkyl polyglucosides can be used as anionic surfactants ,
  • the tablet system contains at least one lauryl sulfate as the anionic surfactant.
  • lauryl sulfate include the products known under the trade name Texapon® K1296 PLV, Sulfopon® 1214 G, Empicol® LXS 95 / S, Lauropan® 93, Rewopol® NLS 28, Sulfopon® WA 2. sulfonates
  • the surfactants of the sulfonate type are preferably Cg. 13 alkyl benzene sulfonates and olefin sulfonates into consideration.
  • Olefin sulfonates are mixtures of alkene and hydroxyalkanesulfonates and disulfonates, such as are obtained, for example, from C 12-18 monoolefins with a terminal or internal double bond by sulfonation with gaseous sulfur trioxide and subsequent alkaline or acid hydrolysis of the sulfonation products.
  • alkanesulfonates obtained from C 12-18 alkanes, for example by sulfochlorination or sulfoxidation with subsequent hydrolysis or neutralization.
  • the esters of D-sulfofatty acids for. B. the D-sulfonated methyl esters of hydrogenated coconut, palm kernel or tallow fatty acids are suitable.
  • Suitable, particularly foaming anionic surfactants of the sulfonate type are the salts, in particular the alkali metal salts, of alk (en) ylsulfosuccinic acid, which are also referred to as sulfosuccinates or as sulfosuccinic acid esters.
  • alk (en) ylsulfosuccinic acid which are also referred to as sulfosuccinates or as sulfosuccinic acid esters.
  • these include the mono- and / or diesters of sulfosuccinic acid with alcohols, preferably fatty alcohols and in particular ethoxylated fatty alcohols.
  • the ethoxylated fatty alcohols can have a normal or narrow homolog distribution.
  • Preferred sulfosuccinates contain C 8 . 18 fatty alcohol residues or mixtures thereof.
  • the sulfosuccinates preferably contain an
  • the sulfosuccinates preferred according to the invention include, for example, Rewopol® SB F 12 P, Sulfosuccinat® S3, Sulfosuccinat® S2, Disponil® SUS 65, Texapon® SB 3 and Texin® SB 3.
  • the group of nonionic surfactants mainly includes alkoxylated alcohols, alkoxylated fatty acid esters, alkyl polyglucosides and amine oxides.
  • Fatty acid alkanolamides and fatty acid alkanolamide ethoxylates can also be used as foam stabilizers.
  • alkoxylated fatty alcohols have different application properties. They are used, among other things, as emulsifiers and solubilizers for fats and oils in shower and foam baths.
  • ethoxylated, especially primary alcohols with preferably 8 to 18 carbon atoms and an average of 1 to 12 moles of ethylene oxide (EO) are used per mole of alcohol.
  • the alkyl radical can be linear or preferably methyl-branched in the 2-position. Mixtures of alkoxylated alcohols with linear and methyl-branched radicals, as usually occur with oxo alcohols, can also be used.
  • the C 12-14 alcohols with 3 EO or 4 EO, C 1-4 alcohol with 7 EO, C 13-15 alcohols with 3 EO, 5 EO, 7 EO or 8 EO, C 12 are particularly preferred.
  • the degrees of ethoxylation given represent statistical averages, which can be an integer or a fraction for a specific product.
  • Alcohol ethoxylates with a narrow homolog distribution can also be used.
  • fatty alcohols with more than 12 EO can also be used. Examples of this are tallow fatty alcohol with 14 EO, 25 EO, 30 EO or 40 EO.
  • alkylglycosides which are prepared from sugars and alcohols with acetalization as further nonionic surfactants.
  • These surfactants are particularly well tolerated by the skin and, in conjunction with anionic surfactants, develop particularly fine-bubble and stable foams.
  • anhydrous sugar surfactants as described in DE 43 40 015 and DE 44 04 633, are preferred.
  • Sprayable, water-free APG / nonionic surfactant mixtures as described in DE 198 58 923.3, can also be advantageous.
  • Preferred sugar components of the alkyl glycosides (glycoses) are glucose, but also fructose, mannose, galactose, talose, gulose, allose, idose, arabinose, xylose, lyxose, ribose and mixtures thereof.
  • Preferred because of the easy availability and the good application properties are the acetalization products of glucose with fatty alcohols which, for. B. are available from natural oils and fats by known methods.
  • polysaccharides such as. B. starch and maltodextrin and the accessible from technical alcohol synthesis oxo and Ziegleralkohole are suitable starting materials.
  • both monoglycosides and oligoglycosides in which a sugar residue is glycosidically bonded to the fatty alcohol are suitable.
  • Mixtures of mono- and oligoglycosides, which in turn represent mixtures of different isomeric forms, are usually present in the commercial products.
  • Alkyl glycosides are preferably of the formula R 1 0 (G) x, where R 1 is a primary linear or methyl-branched, methyl-branched in particular in the 2-position aliphatic radical having 8 to 22, preferably 12 to 18 carbon atoms, and G is a glycose unit having Represents 5 or 6 carbon atoms, preferably glucose.
  • the degree of oligomerization x which indicates the distribution of monoglycosides and oligoglycosides, is any number between 1 and 10; x is preferably 1 to 2, in particular 1 to 1 to 4.
  • Linear alkyl polyglucosides ie alkyl glycosides based on glucose and an n-alkyl radical, are preferably used.
  • nonionic surfactants which can be used according to the invention are alkoxylated, preferably ethoxylated or ethoxylated / propoxylated, fatty acid esters, preferably of alcohols having 1 to 4 carbon atoms or glycerol, for example alkoxylated fatty acid methyl esters, which are described in Japanese patent application JP 58217598 or which are described in the international patent application WO-A-90/13533.
  • amine oxides preferably ethoxylated or ethoxylated / propoxylated, fatty acid esters, preferably of alcohols having 1 to 4 carbon atoms or glycerol, for example alkoxylated fatty acid methyl esters, which are described in Japanese patent application JP 58217598 or which are described in the international patent application WO-A-90/13533.
  • Amine oxides are obtained by reacting tertiary amines with hydrogen peroxide. These are readily water-soluble, biodegradable surfactants, which are particularly suitable for bath additives because of their mild cleaning action, their excellent skin tolerance, their foam stability and low toxicity. These include, for example, N-coconut alkyl-N, N-dimethylamine oxide and N-tallow alkyl-N, N-dihydroxyethylamine oxide.
  • Polyhydroxy fatty acid amides also have good foam stability, particularly in combination with anionic surfactants. They are biodegradable and very well tolerated by the skin.
  • Polyhydroxy fatty acid amides of the formula R 2 CONR 3 [Z] are suitable, in which R 2 CO is an aliphatic acyl radical having 6 to 22 carbon atoms, R 3 is hydrogen, an alkyl or hydroxyalkyl radical having 1 to 4 carbon atoms and [Z] is a linear one or branched polyhydroxyalkyl radical having 3 to 10 carbon atoms and 3 to 10 hydroxyl groups.
  • the polyhydroxy fatty acid amides are known substances which can usually be obtained by reductive amination of a reducing sugar with ammonia, an alkylamine or an alkanolamine and subsequent acylation with a fatty acid, a fatty acid alkyl ester or a fatty acid chloride.
  • the group of polyhydroxy fatty acid amides also includes compounds of the formula
  • R 4 is a linear or branched alkyl or alkenyl radical having 7 to 12 carbon atoms
  • R 5 is a linear, branched or cyclic alkyl radical or an aryl radical is 2 to 8 carbon atoms
  • R 6 is a linear, branched or cyclic ß
  • [Z] stands for a linear polyhydroxyalkyl radical whose alkyl chain is substituted with at least two hydroxyl groups, or alkoxylated, preferably ethoxylated or propoxylated derivatives of this radical.
  • [Z] is preferably obtained by reductive amination of a reduced sugar, for example glucose, fructose, maltose, lactose, galactose, mannose or xylose.
  • a reduced sugar for example glucose, fructose, maltose, lactose, galactose, mannose or xylose.
  • the N-alkoxy- or N-aryloxy-substituted compounds can then, for example in accordance with international application WO-A-95/07331, be converted into the desired polyhydroxy fatty acid amides by reaction with fatty acid methyl esters in the presence of an alkoxide as catalyst.
  • Amphoteric surfactants can also be present in the preparations according to the invention. In addition to good skin and mucous membrane tolerance, they have good foaming and cleaning properties and have e.g. T. microbicidal effect on.
  • Ampholytic surfactants are surface-active compounds which, in addition to a C 8 -C 18 -alkyl or acyl group, contain at least one free amino group and at least one -COOH or -S0 3 H group in the molecule. They have the property of reacting in acidic solution by protonation on the tertiary nitrogen atom like cationic surfactants and in the alkaline range by salt formation on the carboxyl group like anionic surfactants. Amphoteric surfactants can form internal salts.
  • amphoteric surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having 8 to 18 C atoms in the alkyl group.
  • Particularly preferred amphoteric surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate, C 12 . 18 acyl sarcosine and cocoamphoglycinate.
  • the last group includes, for example, the product commercially available under the trademark Dehyton®G. ⁇ k Zwitterionic surfactants
  • Zwitterionic surfactants have also been known for a long time and are used in a large number of cosmetic formulations.
  • Zwitterionic surfactants are surface-active compounds that contain at least one quaternary ammonium group and at least one -COO - or -SO group in the molecule.
  • the best known and most widespread group of these surfactants is that of betaine surfactants, in which the quaternary ammonium group carries two methyl substituents.
  • Suitable zwitterionic betaine surfactants include N-alkyl-N, N-dimethylammonium glycinate, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate, for example cocoacylaminopropyldimethylammoniumglycinate, and 2-alkyl-3-carboxylm hydroxyethylimidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and the cocoacylaminoethylhydroxyethylcarboxymethylglycine.
  • cocoacylaminopropyldimethylammonium glycinates which are known under the INCI name Cocamidopropylbetaine, in particular Cocoamidopropylbetaine, which is derived from C 8 -C 18 coconut or palm kernel fatty acids.
  • Cocamidopropylbetaine in particular Cocoamidopropylbetaine, which is derived from C 8 -C 18 coconut or palm kernel fatty acids.
  • Such products are e.g. B. commercially under the trademark Dehyton®K.
  • the bathing tablet system contains at least one phase containing care components (care phase), which dissolves slowly or with a time delay.
  • care phase preferably contains no shower system.
  • care components are generally understood to mean compounds which have a caring influence on the skin. These include lipids and lipophilic compounds, such as hydrocarbons, silicone oils, higher alcohols and fatty acids, as well as fats, oils and waxes that re-moisturize the skin, or curative or systemic substances such as ceramides, which are able to compensate for a lack of homolayer lipids. Vitamins, lipoproteins, glycolipids, phospholipids and plant extracts with dermatological active ingredients can also be used as care components. Possible care components are listed below, this list being intended to be exemplary and not limiting. care components
  • fatty acid and fatty alcohol esters include the monoesters of the fatty acids with alcohols with 1 to 24 carbon atoms or with glycerol.
  • This group of substances concerns the products of the esterification of fatty acids with 8 to 24 carbon atoms such as, for example, caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmoleic acid, stearic acid, isostearic acid, oleic acid, Elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaleostearic acid, arachic acid, gadoleic acid, behenic acid and erucic acid and their technical mixtures, the z.
  • alcohols such as isopropyl alcohol, capro alcohol, caprylic alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, stostearic alcohol, Oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, elaeostearyl alcohol, arachyl alcohol, gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassidyl alcohol and their technical mixtures, the z.
  • alcohols such as isopropyl alcohol, capro alcohol, caprylic alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, stostearic alcohol
  • the hydrogenated or hardened oils e.g. B. hydrogenated soybean oil, castor oil and peanut oil can be used.
  • Vaseline, paraffin and silicone oils are also suitable as oil bodies.
  • the latter include a. Dialkyl and alkylarylsiloxanes, such as dimethylpolysiloxane and methylphenylpolysiloxane, and their alkoxylated and quaternized analogs.
  • the fatty alcohols used can be saturated or unsaturated and linear or branched.
  • decanol, octanol, octenol, dodecenol, decenol, octadienol, dodecadienol, decadienol, oleyl alcohol can be used in the context of the invention.
  • the fatty alcohols are usually obtained from the esters of the fatty acids by reduction.
  • Fatty alcohol cuts can also be used according to the invention, which can be obtained by reducing naturally occurring fats and oils, such as. B. beef tallow, peanut oil, rape oil, cottonseed oil, soybean oil, sunflower oil, palm kernel oil, linseed oil, castor oil, corn oil, rapeseed oil, sesame oil, cocoa butter and coconut oil.
  • synthetic alcohols e.g. B. the linear, even-numbered fatty alcohols of Ziegler synthesis (Alfole®) or the partially branched alcohols from oxosynthesis (Dobanole®) can be used.
  • water-soluble proteins or water-soluble derivatives of insoluble proteins include elastin, collagen, keratin, milk protein, soy protein, silk protein, oat protein, pea protein, almond protein and wheat protein hydrolyzates, their condensation products with fatty acids and quaternized protein hydrolyzates.
  • Vitamin and vitamin precursors such as tocopherols, vitamin A, niacinic acid and niacinic acid amide, other vitamins of the B complex, vitamin C, vitamin F and especially biotin.
  • panthenol, its derivatives in particular the esters and ethers of panthenois, and cationically derivatized panthenols. Individual representatives are, for example, panthenol triacetate, panthenol monoethyl ether and its monoacetate, and cationic panthenol derivatives.
  • Plant extracts or active ingredients derived from them Plant extracts or active ingredients derived from them
  • Plant extracts which are usually produced by extraction of the entire plant, but in individual cases also exclusively from flowers and / or leaves of the plant, in particular dry extracts, can be suitable as a care component.
  • plant extracts which can be used according to the invention, reference is made in particular to the extracts which are listed in the table beginning on page 44 of the 3rd edition of the Guide to the Declaration of Ingredients for Cosmetics, published by the Industrie said elaboratethronosti- und Waschstoff eV (IKW), Frankfurt.
  • the extracts from almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi and melon are particularly preferred.
  • Mixtures of several different plant extracts can also be present in the agents according to the invention. Water, alcohols and mixtures thereof can be used as extractants for the production of the plant extracts mentioned. Special active ingredients or plant extract concentrates can be obtained by concentrating the extracts.
  • Honey extracts which are obtained in an analogous manner to the plant extracts and usually contain 1-10% by weight, in particular 3-5% by weight, of active substance.
  • Phospholipids for example soy lecithin, egg lecithin and cephalins
  • Vesicle-forming lipids such as B: lecithin, cholesterol, sitosterol, ceramides, cerebroside and sphingomyeline
  • Care components especially oils and fats, usually have a negative effect on the cleaning effect of surfactants and prevent stable foam formation.
  • the care phase must be released slowly or with a time delay, so that intensive skin cleaning is made possible before the nourishing effect begins. This can be achieved, for example, by the fact that the care phase does not contain an effervescent system and is predominantly composed of water-soluble salts and possibly a carrier material.
  • the cleaning phase usually IS should solve in 1 - 5 minutes, the dissolution time of the care phase should be 7 - 15 minutes.
  • a preferred embodiment of the tablet system is characterized in that the care phase contains 40.0-95.0% by weight of an anhydrous mixture of at least one anhydrous and water-soluble salt of carbonic acid and at least one anhydrous and water-soluble salt of a hydroxycarboxylic acid.
  • Combinations of alkali metal bicarbonates and alkali metal salts of a hydroxycarboxylic acid are preferred for the purposes of the invention, in particular the combination of sodium bicarbonate and sodium citrate.
  • Mixtures of hydrogen carbonate / carbonate and salts of various hydroxy carboxylic acids can also be used.
  • the molar ratio between the salt of carbonic acid and the salt of hydroxycarboxylic acid in this phase is preferably 0.5-20, preferably 1-10 and in particular 1-5.
  • a molar ratio between 3-4 is preferred. It is known from EP 0 711 827 that the disintegration times are accelerated by citrates.
  • surfactants can be added to this phase.
  • a preferred embodiment of the tablet system is characterized in that the care phase additionally contains at least one surfactant. The same proportions of surfactant are usually contained in the cleaning and maintenance phases.
  • a further preferred embodiment of the tablet system is characterized in that the care phase contains 0.1-20% by weight of at least one care component. Possible care components have already been mentioned.
  • the bathing tablet preferably contains at least one fat component as a care component.
  • the fat component is contained in amounts of 1-20% by weight, preferably 1-10% by weight and in particular 3-8% by weight.
  • the usual refatting agents can be used as fat components, for example natural fats and waxes, higher fatty alcohols and higher fatty acids, synthetic mono-, di- and triglycerides and synthetic esters such as isopropyl myristate. Fat components of native origin are preferably used.
  • a particularly preferred embodiment of the tablet system is characterized in that the cleaning phase a) 30-50% by weight of an anhydrous and water-soluble hydrogen carbonate or carbonate, b) 10-25% by weight of an anhydrous and water-soluble hydroxycarboxylic acid, c) 10- 20% by weight of an anhydrous and water-soluble salt of hydroxycarboxylic acid, d) 0.1-5% by weight of cellulose and e) 10-25% by weight of an anionic surfactant and the care phase f) 30-50% by weight of an anhydrous and water-soluble hydrogen carbonate or carbonate, g) 20-50% by weight of an anhydrous and water-soluble salt of hydroxycarboxylic acid, h) 10-25% by weight of an anionic surfactant and i) 1-15% by weight of a fat component.
  • a preferred embodiment of the tablet system therefore additionally contains at least one dye in the care phase.
  • Suitable dyes the selection of which is not difficult for a person skilled in the art, have a long shelf life and are insensitive to the other ingredients of the compositions and are water-soluble. They must be lightfast, temperature stable and physiologically harmless and are usually contained in an amount below 1% by weight, based on this phase. Suitable classes of dyes are known to the person skilled in the art from the relevant specialist literature.
  • absorbents for example, absorbents, solubilizers and lubricants, other disintegrants and inorganic salts can be used as formulation auxiliaries which enable good tableting.
  • the formulation auxiliaries are present in the bath tablet in a total amount of usually 1-70.0% by weight, preferably 5-20% by weight and in particular 8-15% by weight.
  • Suitable absorbing substances are, for. B. cyclodextrin, dextrin, starch and / or finely divided silica or silicates.
  • suitable lubricants are talc, metal soaps, in particular stearates, and also siloxanes, sucrose fatty acid esters, microcrystalline cellulose or polyols.
  • polyol lubricants polyethylene glycols (for example PEG 6000, PEG 8000, PEG 10000 and PEG 20000) are particularly suitable, preferably those which have a molecular weight of 5000-7000.
  • mineral salts or mixtures thereof are added to the tablets, the salts preferably being composed of the cations lithium, sodium, potassium, magnesium, calcium, iron, ammonium or manganese and the anions chloride, fluoride, sulfate or nitrate.
  • a preferred embodiment of the tablet system contains silicon dioxide, pyrogenic silica and / or silicate as formulation aid.
  • Amorphous and highly disperse or pyrogenic silicas with a high absorption capacity e.g. Aerosil®, in particular Aerosil® 200. Aerosil® is usually in all phases / layers of the tablet in an amount of 0.1-3.0% by weight, preferably 0.1-1.0% by weight and in particular 0 , 2 - 0.8 wt .-% contain.
  • Silicas can contain multivalent ions, e.g. As calcium ions bind and thus support the cleaning action of the surfactants and also have dispersing properties.
  • Such formulation aids are u. a. known from detergent technology.
  • aluminosilicates of the zeolite type are particularly suitable, as are layered magnesium and sodium silicates, as described in EP 0 164 514 and in DE 19754292.
  • Fragrances are an essential olfactory component of the bathing tablet. They are added to the tablets according to the invention in order to improve the aesthetic impression of the products and to provide the consumer with a sensorically "typical and unmistakable" product in addition to the washing and care performance.
  • perfume oils or fragrances individual fragrance compounds, e.g. B. the synthetic products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type can be used. Fragrances of the ester type are e.g. B.
  • the ethers include, for example, benzyl ethyl ether, the aldehydes z. B.
  • the linear alkanals with 8-18 C atoms citral, citronellal, citronellyloxyacetaldehyde, cyclamen aldehyde, hydroxycitronellal, lilial and bourgeonal, to the ketones z.
  • perfume oils can also contain natural fragrance mixtures such as are available from plant sources, e.g. B. pine, citrus, jasmine, patchouly, rose or ylang-ylang oil. Also suitable are muscatel, sage oil, chamomile oil, clove oil, corn oil, mint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, olibanum oil, galbanum oil and labdanum oil as well as orange blossom oil, neroliol, orange peel oil and sandalwood oil.
  • the fragrance content is usually 1-5% by weight of the entire tablet.
  • the fragrances can be incorporated directly into the agents according to the invention, but it can also be advantageous to apply the fragrances to carriers which enable a slower and thus long-lasting fragrance release. Cyclodextrins, for example, have proven themselves as such carrier materials.
  • the raw materials of the cleaning and maintenance phases were homogenized separately in a Lödige M5 mixer.
  • the perfume was only added to the cleaning and care phase towards the end of the homogenization.
  • the bath tablets were produced on a laboratory hand press of the type PW 40 from Paul Otto Weber.
  • a round tool made of hardened steel with a diameter of 40 mm was used as the pressing tool (model 10).
  • the tablet (total weight: 25 g) was composed of two phases (layers). After the first phase (17 g) was pressed at 2 kN, the second phase (8 g) was added and the entire mass was pressed at 8 kN.
  • Pressing forces of less than 6 kN were unsuitable because the resulting tablets disintegrated too easily. Compression forces of more than 15 kN also proved unsuitable because the tablets could then no longer be removed from the compression mold. Tablets with a lower surfactant content can be pressed at a higher pressure.
  • the disintegration times depend on the baling pressure.
  • the raw materials of the cleaning and care phase were homogenized separately, the perfume was again added to the cleaning and care phase only towards the end of the homogenization, and the cleaning and care phase was compressed into individual tablets.
  • the same apparatus was used for the production of the tablets as for the production of the 2-phase bathing tablet.
  • the cleaning tablet (weight: 17 g) was pressed at 6, 7, 8 and 9 kN. Depending on the pressing force, these tablets dissolved in 2 L of water at approx. 40 ° C. in 2 min 15 sec, 2 min 20 sec, 2 min 25 sec and 2 min 35 sec.
  • the care tablet (weight: 8 g) was pressed with a pressing force of 8-10 kN; here the dissolution times were 7-10 minutes.
  • Aerosil® 200 INCI silica manufacturer: Degussa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un système de pastille de bain à phases multiples, dont les phases se dissolvent dans l'eau à des vitesses différentes ou à des moments différents (décalage dans le temps). La phase purifiante à base d'agent tensioactif contient un système effervescent et est rapidement dissoute. Cela permet une purification intensive au début du bain. La phase de soin se dissout ensuite plus lentement et de manière décalée dans le temps et permet un second traitement de soin de la peau.
PCT/EP2000/009834 1999-10-16 2000-10-07 Pastilles de bain WO2001028513A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU28340/01A AU2834001A (en) 1999-10-16 2000-10-07 Bath tablets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19950018.5 1999-10-16
DE1999150018 DE19950018A1 (de) 1999-10-16 1999-10-16 Badetabletten

Publications (2)

Publication Number Publication Date
WO2001028513A2 true WO2001028513A2 (fr) 2001-04-26
WO2001028513A3 WO2001028513A3 (fr) 2001-11-01

Family

ID=7925955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009834 WO2001028513A2 (fr) 1999-10-16 2000-10-07 Pastilles de bain

Country Status (3)

Country Link
AU (1) AU2834001A (fr)
DE (1) DE19950018A1 (fr)
WO (1) WO2001028513A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072104A2 (fr) * 2006-12-13 2008-06-19 Kimberly-Clark Worldwide, Inc. Comprimés multiphases pour le bain/la douche
WO2011154727A3 (fr) * 2010-06-07 2012-06-07 Cosmetic Warriors Ltd Composition
EP2671615A1 (fr) * 2012-06-05 2013-12-11 Merz Pharma GmbH & Co. KGaA Additif solide de bain avec un profil de dissémination visuel et olfactoric à l'effect retardé
WO2020114679A1 (fr) * 2018-12-06 2020-06-11 Beiersdorf Ag Composition cosmétique solide nettoyante
WO2020210184A1 (fr) * 2019-04-11 2020-10-15 Basf Se Comprimé de nettoyage
US11975090B2 (en) 2019-10-30 2024-05-07 Johnson & Johnson Consumer Inc. Sulfate-free, foamable solid cleanser comprising an isethionate/betaine surfactant system

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT13075U1 (de) * 2012-06-05 2013-05-15 Merz Pharma Gmbh & Co Kgaa Fester Badezusatz mit retardiertem olfaktorischem und visuellem Freisetzungswirkungsprofil
EP2808059A1 (fr) * 2013-05-29 2014-12-03 Merz Pharma GmbH & Co. KGaA Additif de bain comprenant 2 composants avec un delai de liberation retardee d'un colorant dependant de la matrice
GB201404178D0 (en) * 2014-03-10 2014-04-23 Cosmetic Warriors Ltd Composition
US9792516B2 (en) 2016-01-26 2017-10-17 Next Biometrics Group Asa Flexible card with fingerprint sensor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU57909A1 (fr) * 1969-02-04 1970-08-04
EP0930064A2 (fr) * 1997-12-20 1999-07-21 Merz & Co. GmbH & Co. Additif pour le bain sous la forme de comprimé effervescent à utiliser dans la balneothérapie, son procedé de préparation et son utilisation
WO1999040171A1 (fr) * 1998-02-04 1999-08-12 Unilever Plc Compositions detergentes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02142722A (ja) * 1988-11-24 1990-05-31 Lion Corp 固形状浴用剤
JP2841517B2 (ja) * 1989-08-11 1998-12-24 株式会社ツムラ 入浴剤
JPH04128218A (ja) * 1990-09-20 1992-04-28 Nonogawa Shoji Kk 浴用剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU57909A1 (fr) * 1969-02-04 1970-08-04
EP0930064A2 (fr) * 1997-12-20 1999-07-21 Merz & Co. GmbH & Co. Additif pour le bain sous la forme de comprimé effervescent à utiliser dans la balneothérapie, son procedé de préparation et son utilisation
WO1999040171A1 (fr) * 1998-02-04 1999-08-12 Unilever Plc Compositions detergentes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 199119 Derwent Publications Ltd., London, GB; Class D21, AN 1991-136889 XP002166145 & JP 03 074321 A (TSUMURA & CO), 28. März 1991 (1991-03-28) *
PATENT ABSTRACTS OF JAPAN vol. 014, no. 386 (C-0750), 21. August 1990 (1990-08-21) & JP 02 142722 A (LION CORP), 31. Mai 1990 (1990-05-31) *
PATENT ABSTRACTS OF JAPAN vol. 016, no. 394 (C-0976), 21. August 1992 (1992-08-21) & JP 04 128218 A (NONOGAWA SHIYOUJI:YUUGEN), 28. April 1992 (1992-04-28) *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072104A2 (fr) * 2006-12-13 2008-06-19 Kimberly-Clark Worldwide, Inc. Comprimés multiphases pour le bain/la douche
WO2008072104A3 (fr) * 2006-12-13 2008-11-06 Kimberly Clark Co Comprimés multiphases pour le bain/la douche
WO2011154727A3 (fr) * 2010-06-07 2012-06-07 Cosmetic Warriors Ltd Composition
JP2013528203A (ja) * 2010-06-07 2013-07-08 コスメティック ウォリアーズ エルティーディー 組成物
US8697621B2 (en) 2010-06-07 2014-04-15 Cosmetic Warriors Ltd. Surfactant product comprising two distinct effervescent compositions
AU2011263481B2 (en) * 2010-06-07 2016-07-28 Cosmetic Warriors Ltd Effervescent bath composition
EP2671615A1 (fr) * 2012-06-05 2013-12-11 Merz Pharma GmbH & Co. KGaA Additif solide de bain avec un profil de dissémination visuel et olfactoric à l'effect retardé
WO2020114679A1 (fr) * 2018-12-06 2020-06-11 Beiersdorf Ag Composition cosmétique solide nettoyante
CN113164332A (zh) * 2018-12-06 2021-07-23 拜尔斯道夫股份有限公司 固体美容清洁组合物
WO2020210184A1 (fr) * 2019-04-11 2020-10-15 Basf Se Comprimé de nettoyage
US11975090B2 (en) 2019-10-30 2024-05-07 Johnson & Johnson Consumer Inc. Sulfate-free, foamable solid cleanser comprising an isethionate/betaine surfactant system

Also Published As

Publication number Publication date
DE19950018A1 (de) 2001-04-19
AU2834001A (en) 2001-04-30
WO2001028513A3 (fr) 2001-11-01

Similar Documents

Publication Publication Date Title
DE69418477T2 (de) Alkylglykosiden enthaltendes konzentrat und seine anwendungen
DE60100032T2 (de) Kosmetisches Reinigungszusammensetzung
EP1259220A1 (fr) Gel nettoyant pour la peau a effet chauffant
NO314218B1 (no) Hudvasksammensetning, fremgangsmåte for fremstilling av samme, anvendelse av samme for fremstilling av medikament og anvendelse av samme vedkosmetisk behandling
JPH08505875A (ja) クレンジング組成物
DE60017595T2 (de) Stabile flüssigkeiten mit hohem glycerolgehalt, die sulfosuccinsäuremonoester enthalten
BR112020012228B1 (pt) Composição aquosa espumante, dispositivo cosmético, processo cosmético e uso cosmético da composição
JP4467712B2 (ja) 洗浄組成物
WO2001028513A2 (fr) Pastilles de bain
DE102019210158A1 (de) Feste kosmetische Reinigungsmittel
EP1754518A1 (fr) Composition auto-chauffante pour le nettoyage de la peau
WO2015189049A1 (fr) Utilisation d'une composition de nettoyage cosmétique comme probiotique
DE10007321A1 (de) Reinigungsschaum
EP2033622B1 (fr) Produit de nettoyage cosmétique ayant un pH réduit
EP1700619B1 (fr) Composition détersive
KR20160061875A (ko) 피부 세정제 조성물
JP2003096489A (ja) 固形石鹸
DE602004011266T2 (de) Geordnete flüssigkristalline reinigungszusammensetzung mit suspendierter luft
WO2016083043A1 (fr) Savon contenant des savons solides cosmétiques et microémulsions
JP2007246510A (ja) 起泡性化粧品組成物
WO2004073666A1 (fr) Preparation de lavage cosmetique moussante
WO1990006105A2 (fr) Melanges tensio-actifs
JP2002226359A (ja) 脂肪酸石鹸系洗顔クリーム
WO2016071187A1 (fr) Lotion de douche
DE10126706B4 (de) Handgeschirrspülmittelformkörper mit hohem Tensidgehalt

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ HU JP MX NO PL SK US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ HU JP MX NO PL SK US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP